177Lu Lu-DOTA-TATE in patients newly diagnosed with Grade 1 and Grade 2 advanced GEP-NET

A phase III multi-center, randomized, open-label study to evaluate the efficacy and safety of [177Lu]Lu-DOTA-TATE in patients newly diagnosed with Grade 1 and Grade 2 (Ki-67 <10%) advanced GEP-NET with high disease burden (NETTER-3) Protocol No.: CAAA601A62301

Disease Types: Gastrointestinal, Gastroenteropancreatic neuroendocrine tumors

Available at: Roanoke

A phase III multi-center, randomized, open-label study to evaluate the efficacy and safety of [177Lu]Lu-DOTA-TATE in patients newly diagnosed with Grade 1 and Grade 2 (Ki-67 <10%) advanced GEP-NET with high disease burden (NETTER-3) Protocol No.: CAAA601A62301

For More Information:

https://clinicaltrials.gov/study/NCT06784752?term=%09NCT06784752&rank=1